Welcome to our dedicated page for Oklo news (Ticker: oklo), a resource for investors and traders seeking the latest updates and insights on Oklo stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Oklo's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Oklo's position in the market.
Oklo (NYSE: OKLO) and Blykalla expanded a transatlantic strategic partnership to broaden collaboration on fast reactor commercialization. Blykalla plans U.S. capital and engineering contributions on the scale of $100–200 million and 30–40 engineers, subject to final planning and approvals.
The agreement targets reactor pilot project support, neutronics and thermohydraulics analyses, and exploration of fast‑neutron irradiation testing using Oklo facilities, all within applicable U.S. laws, export controls and DOE program frameworks.
Oklo (NYSE: OKLO) announced that CEO and co-founder Jacob DeWitte was appointed to the U.S. President’s Council of Advisors on Science and Technology (PCAST) on March 25, 2026. DeWitte will join leaders from science, engineering, and industry to advise on national science and technology policy.
The Council is co-chaired by David Sacks and Michael Kratsios and includes senior figures from technology and business.
Oklo (NYSE: OKLO) announced U.S. Department of Energy approval of the Nuclear Safety Design Agreement (NSDA) for Atomic Alchemy’s Groves Isotopes Test Reactor in Lockhart, Texas. The NSDA clears the facility to submit its Preliminary Documented Safety Analysis (PDSA) and move into the next DOE-reviewed execution phase.
The subsidiary previously signed an Other Transaction Agreement (OTA) and is targeting criticality by July 4, 2026. The pilot aims to develop domestic radioisotope production capacity for medical, research, space, and national security uses.
Oklo (NYSE: OKLO) published its full-year 2025 financial results and business update and will host a conference call on March 17, 2026 at 2:00 p.m. PT / 5:00 p.m. ET.
Jacob DeWitte, co-founder and CEO, and Craig Bealmear, CFO, will speak. A live webcast is available via the company investor relations Events & Presentations page, with an archive accessible for 12 months after the call.
Oklo (NYSE: OKLO) subsidiary Atomic Alchemy received a U.S. Nuclear Regulatory Commission materials license on March 17, 2026, to handle, process, and distribute isotopes from its Idaho Radiochemistry Laboratory.
The license authorizes work with up to 2 Curies of Ra-226 and sealed sources of Co-60 and Am-241, enabling initial commercial sales, recovery of disused radium feedstock, and development of processes for a planned multi-reactor isotope foundry.
Oklo (NYSE: OKLO) signed a U.S. Department of Energy Other Transaction Agreement (OTA) and received DOE Idaho approval of a Nuclear Safety Design Agreement (NSDA) for its Aurora powerhouse at Idaho National Laboratory (Aurora-INL) on March 17, 2026. Oklo has requested DOE review of its Preliminary Documented Safety Analysis (PDSA) and plans subsequent NRC licensing for commercial operations.
The NSDA is the first step in DOE’s Reactor Pilot Program (RPP) authorization pathway; Aurora-INL is linked to Oklo’s Aurora Fuel Fabrication Facility (A3F), whose NSDA and PDSA were approved in late 2025. Oklo holds site access and secured fuel from Experimental Breeder Reactor II.
Oklo (NYSE: OKLO) and Centrus (NYSE: LEU) announced they will pursue discussions to form a joint venture focused on deconversion services for HALEU and related fuel‑cycle technologies at Centrus’ Piketon site in Pike County, Ohio.
The plan would co‑locate deconversion with enrichment near Oklo’s planned 1.2 GW power campus to expand domestic HALEU fuel capacity, improve efficiency, reduce shipping complexity, and coordinate regulatory and R&D engagement with federal and local stakeholders.
Oklo (NYSE: OKLO) will release full-year 2025 financial results after market close on Tuesday, March 17, 2026, followed by a business update conference call at 5:00 p.m. ET / 2:00 p.m. PT.
CEO Jacob DeWitte and CFO Craig Bealmear will host the call. A live webcast and replay will be available, and the investor presentation and results will be posted at oklo.com/investors.
Oklo and Meta (NASDAQ: META) agreed to advance development of a scalable nuclear power campus in Pike County, Ohio, targeting 1.2 GW of capacity. Meta will prepay for power and provide funding to support Oklo’s Aurora powerhouse deployment, including early procurement such as nuclear fuel. Oklo finalized purchase of 206 acres for the site, with pre-construction and site characterization slated for 2026. The first phase is targeted to come online as early as 2030, with incremental expansion to reach 1.2 GW by 2034. The agreement aims to support Meta data centers, create construction and operations jobs, and add new local and state tax revenues.
Oklo (NYSE: OKLO) announced on January 7, 2026 that it signed a U.S. Department of Energy Other Transaction Agreement (OTA) to support design, construction, and operation of a Radioisotope Pilot Facility under the DOE Reactor Pilot Program.
Oklo’s Atomic Alchemy subsidiary will build and operate the pilot plant to generate data for future commercial radioisotope production, while withdrawing its previously submitted NRC construction permit application for Meitner-1 to focus resources under DOE authorization.